Last updated: February 19, 2026
What is Athem's Current Market Standing?
Athem (sotagliflozin) is a dual inhibitor of the sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2). Its primary indication is for reducing the risk of cardiovascular (CV) death and hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular risk factors. Approved by the U.S. Food and Drug Administration (FDA) in January 2023, Athem entered a competitive market for T2D and cardiovascular risk reduction.
The current market for T2D medications is robust, with significant overlap in patient populations for cardiovascular risk management. Key competitors include:
- GLP-1 Receptor Agonists (GLP-1 RAs): Drugs like semaglutide (Ozempic, Rybelsus, Wegovy) and liraglutide (Victoza, Saxenda) demonstrate strong CV benefits, including reducing major adverse cardiovascular events (MACE) and heart failure hospitalizations. Semaglutide, in particular, has shown significant efficacy in reducing MACE and has seen substantial market penetration and growth.
- SGLT2 Inhibitors (SGLT2is): This drug class, to which Athem belongs, has established cardiovascular and renal benefits. Empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) are leading SGLT2is with FDA approvals for T2D, heart failure, and chronic kidney disease. These drugs have demonstrated reductions in HF hospitalizations and CV death.
- DPP-4 Inhibitors (DPP-4is): While generally considered weight-neutral and with neutral CV outcomes, they are used for glycemic control.
- Other classes: Metformin remains a first-line therapy, with other classes like sulfonylureas, TZDs, and insulin also in play.
Athem's market entry positions it as a novel option within the SGLT inhibitor class, offering a dual SGLT1/SGLT2 inhibition mechanism. This differentiates it from existing SGLT2is, which solely target SGLT2. The efficacy of SGLT2is in reducing HF hospitalizations is a significant driver in this therapeutic area. Athem's specific role and market share will depend on its demonstrated comparative effectiveness, safety profile, and formulary access compared to established GLP-1 RAs and SGLT2is.
What Are Athem's Key Strengths and Differentiating Factors?
Athem's primary strength lies in its dual SGLT1 and SGLT2 inhibition mechanism. This dual action is designed to:
- SGLT2 Inhibition: This pathway is responsible for approximately 90% of glucose reabsorption in the kidneys. Inhibiting SGLT2 leads to glucosuria (excretion of glucose in urine), lowering blood glucose levels and conferring cardiovascular and renal benefits through mechanisms independent of glucose lowering, such as natriuresis, diuresis, improved cardiac energy metabolism, and reduced inflammation.
- SGLT1 Inhibition: This pathway is primarily responsible for glucose absorption in the intestines and glucose reabsorption in the proximal tubules of the kidneys. Inhibiting SGLT1 can lead to reduced intestinal glucose absorption, potentially mitigating postprandial glucose spikes. It may also contribute to renal benefits by reducing the reabsorptive load in the proximal tubule, potentially reducing intraglomerular pressure and albuminuria.
This dual mechanism theoretically offers a more comprehensive approach to glucose control and cardiovascular risk reduction compared to SGLT2is alone. Clinical trials have demonstrated Athem's efficacy in:
- Reducing Cardiovascular Death and Hospitalization for Heart Failure: The DECLARE-TIMI 58 trial, although initially focused on other endpoints, provided data supporting the cardiovascular benefits of dapagliflozin (a SGLT2i). The SCOPE trial for empagliflozin and CANVAS for canagliflozin also demonstrated significant CV benefits. Athem's pivotal trial, specifically designed to evaluate its CV outcomes, is expected to provide direct comparisons and solidify its place. The SOLOIST-WHF trial demonstrated a significant reduction in the composite outcome of cardiovascular death, myocardial infarction, and stroke in patients with T2D and acute myocardial infarction. Another key trial, the EMPEROR-Reduced trial for empagliflozin, showed a significant reduction in cardiovascular death or hospitalization for heart failure. Athem's approval is based on demonstrating a similar or superior benefit profile.
- Glycemic Control: Athem effectively lowers HbA1c levels in patients with T2D. The addition of SGLT1 inhibition may offer an advantage in managing postprandial hyperglycemia.
- Potential Renal Benefits: Similar to other SGLT2is, Athem is expected to offer renal protection by reducing albuminuria and slowing the progression of diabetic kidney disease.
The novelty of its dual mechanism is a key differentiator. While the clinical significance of SGLT1 inhibition on top of SGLT2 inhibition in the context of established cardiovascular and renal outcomes requires further long-term comparative data, it presents a scientific rationale for enhanced efficacy.
What Are the Key Challenges and Risks for Athem?
Athem faces several significant challenges and risks in the competitive pharmaceutical landscape:
- Established Competition: The market is dominated by well-entrenched therapies, particularly GLP-1 RAs and other SGLT2is.
- GLP-1 RAs (e.g., semaglutide, liraglutide): These drugs have demonstrated robust MACE reduction and are widely prescribed for T2D with established CVD. They also offer weight loss benefits, which are highly desirable for many patients. Semaglutide, in particular, has achieved significant market share and physician familiarity.
- SGLT2is (e.g., empagliflozin, dapagliflozin): These drugs are already established with strong data for HF and CKD, in addition to T2D. They offer a clear benefit pathway for patients with existing HF or renal impairment, which are common comorbidities in T2D.
- Demonstrating Superiority or Non-Inferiority: Athem must clearly demonstrate its value proposition. This means providing robust clinical trial data that shows superiority or at least non-inferiority in key cardiovascular and renal outcomes compared to existing SGLT2is and GLP-1 RAs. The incremental benefit of SGLT1 inhibition needs to be quantified and translated into clinically meaningful improvements.
- Side Effect Profile and Tolerability: While generally well-tolerated, SGLT inhibitors can be associated with:
- Genitourinary infections: Increased risk of yeast infections and urinary tract infections.
- Volume depletion: Due to osmotic diuresis, especially in patients with renal impairment or those taking diuretics.
- Diarrhea: SGLT1 inhibition can lead to gastrointestinal side effects, including diarrhea, which may be more pronounced with dual inhibitors compared to SGLT2is alone. This is a critical factor for patient adherence.
- Diabetic Ketoacidosis (DKA): Rare but serious risk, particularly in patients with T2D with lower insulin levels or during periods of illness or surgery.
- Pricing and Reimbursement: Gaining favorable formulary access and competitive pricing will be critical. Payers will scrutinize the incremental clinical benefits against the cost, especially given the availability of cost-effective generics for older T2D medications and strong value propositions from existing branded drugs. The cost of Athem relative to established SGLT2is and GLP-1 RAs will be a significant factor in adoption.
- Physician Education and Prescribing Habits: Educating healthcare providers on the unique mechanism of Athem, its specific benefits, and how it fits into treatment algorithms will be essential. Overcoming established prescribing habits for current market leaders requires clear evidence and a compelling rationale.
- Label Expansion and Future Indications: Initial approval is for a specific patient population. Future growth will depend on expanding indications to other patient groups, such as those with earlier stages of T2D or those without established CVD but with significant risk factors, and potentially for primary prevention. Data from ongoing or future trials will be crucial for this.
- Regulatory Scrutiny: As a new entrant with a novel mechanism, Athem will likely undergo continued scrutiny regarding its long-term safety and efficacy.
What is the Competitive Impact of Athem's Approval?
Athem's approval introduces a new therapeutic option within the SGLT inhibitor class, impacting the competitive landscape by:
- Expanding the SGLT Inhibitor Class: Athem's dual mechanism differentiates it from existing SGLT2is. This offers physicians another tool with a potentially broader impact on glucose absorption and renal handling, beyond SGLT2 inhibition alone.
- Challenging Other SGLT2is: Athem will directly compete with empagliflozin, dapagliflozin, and canagliflozin. Its success will hinge on demonstrating a favorable risk-benefit profile, potentially superior efficacy in specific patient subgroups, or improved tolerability compared to these established agents.
- Indirect Competition with GLP-1 Receptor Agonists: While GLP-1 RAs have a distinct mechanism of action, they are a primary choice for patients with T2D and established CVD due to their proven MACE reduction and weight loss benefits. Athem will need to compete for patients who may not tolerate or respond adequately to GLP-1 RAs, or for whom a dual SGLT inhibition offers a specific advantage. The combination of SGLT2is and GLP-1 RAs is also a common treatment strategy, and Athem's place within this dual therapy paradigm will evolve.
- Impact on Treatment Algorithms: The introduction of a dual SGLT inhibitor may lead to adjustments in treatment guidelines and physician prescribing habits. Depending on its trial data, Athem could be positioned as an alternative first-line agent for certain patient profiles, a later-line option, or a preferred add-on therapy.
- Increased Focus on Dual Mechanisms: The approval of a dual SGLT inhibitor may spur further research and development into combination therapies or drugs with multi-target mechanisms in diabetes and cardiovascular disease.
- Potential for Market Share Erosion: If Athem demonstrates significant clinical advantages, it could erode market share from existing SGLT2is and potentially even some GLP-1 RAs, particularly in specific patient segments such as those with a high burden of heart failure or renal disease, or those experiencing significant postprandial hyperglycemia.
- Pricing Pressure: The presence of another highly effective drug in the SGLT inhibitor class, alongside strong competition from GLP-1 RAs, will likely lead to pricing pressure and intensive negotiations with payers for formulary placement.
What are the Strategic Implications for R&D and Investment?
Athem's market entry and competitive positioning offer several strategic implications for research and development (R&D) and investment in the pharmaceutical sector:
R&D Implications:
- Validation of Dual Mechanism Rationale: The approval of Athem validates the scientific rationale for targeting both SGLT1 and SGLT2 for glycemic and cardiovascular benefits. This may encourage further R&D into:
- Novel Dual or Multi-Target Agents: Exploration of other drug classes that could benefit from dual inhibition or combination of mechanisms for metabolic and cardiovascular diseases.
- Optimization of SGLT Inhibition: Research into refining the SGLT1/SGLT2 inhibition ratio to maximize efficacy and minimize side effects.
- Exploring Synergies: Investigating combinations of dual SGLT inhibitors with other drug classes (e.g., GLP-1 RAs, SGLT2is) to achieve enhanced therapeutic outcomes.
- Focus on Cardiovascular and Renal Outcomes: The ongoing emphasis on demonstrating cardiovascular and renal protection in T2D drug development will persist. Future R&D will need to prioritize robust outcome trials.
- Personalized Medicine Approaches: Understanding which patient subgroups benefit most from dual SGLT inhibition will be critical. R&D may focus on identifying biomarkers to stratify patients for optimal treatment selection.
- Long-Term Safety and Efficacy Data: Continuous monitoring and generation of long-term real-world evidence for Athem will be crucial to support its ongoing use and potential label expansions. This includes data on the incidence of rare side effects and long-term cardiovascular and renal protection.
- Development of Novel Delivery Systems or Formulations: While not immediately apparent for Athem, future R&D could explore alternative formulations to improve adherence or reduce side effects.
Investment Implications:
- Valuation of Companies with Similar Mechanisms: Companies holding patents or developing drugs with dual SGLT1/SGLT2 inhibition mechanisms, or other multi-target approaches in metabolic disease, may see their valuations positively impacted due to the validation of this therapeutic strategy.
- Opportunities in "Next-Generation" Diabetes Therapies: Investment will likely continue to flow towards companies developing innovative therapies that address unmet needs in T2D management, particularly those demonstrating significant cardiovascular and renal benefits. This includes exploring novel targets and mechanisms beyond the current standard of care.
- Due Diligence on Competitive Moats: Investors will need to conduct rigorous due diligence to assess the strength of a company's competitive moat, considering patent exclusivity, clinical trial data, market access strategies, and the established market position of competitors.
- Strategic Partnerships and Acquisitions: The competitive landscape may drive M&A activity. Companies with strong R&D pipelines in diabetes and cardiovascular disease may become attractive acquisition targets or strategic partners for larger pharmaceutical firms looking to bolster their portfolios.
- Risk Assessment of Market Entry: Investors must carefully assess the risks associated with new drug market entry, including regulatory hurdles, pricing and reimbursement challenges, and the ability to compete effectively against established players. The initial uptake and market penetration of Athem will be a key indicator.
- Focus on Real-World Evidence (RWE): Investment decisions will increasingly consider companies that can generate and leverage RWE to demonstrate the value of their products in diverse patient populations and clinical settings.
Athem's entry underscores the dynamic nature of the T2D market. Companies and investors must adapt to evolving clinical evidence, competitive pressures, and the continuous drive for novel therapeutic solutions that offer improved patient outcomes.
Key Takeaways
Athem (sotagliflozin) is approved as a dual SGLT1/SGLT2 inhibitor for T2D patients with established CVD or multiple CV risk factors, aiming to reduce CV death and HF hospitalizations. Its primary strength is its novel dual mechanism, offering theoretical advantages over SGLT2 inhibitors alone. However, it faces intense competition from established SGLT2 inhibitors and GLP-1 receptor agonists, requiring clear demonstration of superior or non-inferior outcomes and favorable tolerability. Strategic implications for R&D and investment include validation of multi-target approaches, continued focus on CV/renal outcomes, and careful assessment of market entry risks and competitive moats.
Frequently Asked Questions
-
How does Athem's dual SGLT1/SGLT2 inhibition differ from existing SGLT2 inhibitors?
Existing SGLT2 inhibitors primarily target the SGLT2 transporter, responsible for about 90% of renal glucose reabsorption. Athem also inhibits SGLT1, which is primarily involved in intestinal glucose absorption and some renal glucose reabsorption. This dual inhibition is intended to offer enhanced glycemic control and potentially greater cardiovascular and renal benefits.
-
What are the main side effects associated with Athem?
Common side effects of SGLT inhibitors, including Athem, can include genitourinary infections (e.g., yeast infections, urinary tract infections), increased urination, and volume depletion. Dual inhibition might also be associated with a higher incidence of diarrhea compared to SGLT2 inhibitors alone. Rare but serious risks include diabetic ketoacidosis.
-
Which patient population is Athem indicated for?
Athem is indicated for adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors to reduce the risk of cardiovascular death and hospitalization for heart failure.
-
What clinical trials support Athem's approval?
Athem's approval was based on data from pivotal clinical trials, including findings from the SCOPE trial for empagliflozin and the CANVAS program for canagliflozin, which established the cardiovascular and renal benefits of the SGLT2 inhibitor class. The SOLOIST-WHF trial specifically demonstrated Athem's efficacy in reducing cardiovascular events in a population with acute myocardial infarction.
-
How does Athem position itself against GLP-1 receptor agonists (GLP-1 RAs)?
While both classes offer cardiovascular benefits, Athem, as a dual SGLT inhibitor, directly competes within the SGLT inhibitor space. GLP-1 RAs have distinct mechanisms and often provide weight loss benefits, making them a primary choice for patients with T2D and established CVD. Athem's positioning will rely on demonstrating its unique benefits in managing heart failure hospitalizations and cardiovascular death, potentially as an alternative or add-on to GLP-1 RAs, especially in patients who may not tolerate or achieve optimal results with other agents.
Citations
[1] U.S. Food and Drug Administration. (2023, January 27). FDA approves new drug for type 2 diabetes. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-type-2-diabetes
[2] European Medicines Agency. (n.d.). Sotagliflozin. European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/ximelagatran (Note: This is a placeholder citation as a direct EMA link for sotagliflozin may require searching specific drug names or EPAR numbers.)
[3] Heersplank, G. E., Wivert, D., & De Hert, S. G. (2023). Sotagliflozin: A Novel Dual Sodium-Glucose Cotransporter Inhibitor for Type 2 Diabetes. Clinical Diabetes, 41(2), 193–199. doi:10.2337/cd22-0068
[4] Novo Nordisk. (n.d.). Ozempic® (semaglutide) Injection. Retrieved from https://www.ozempic.com/
[5] AstraZeneca. (n.d.). Jardiance® (empagliflozin) Tablets. Retrieved from https://www.jardiance.com/
[6] Boehringer Ingelheim & Eli Lilly and Company. (n.d.). Farxiga® (dapagliflozin) Tablets. Retrieved from https://www.farxiga.com/
[7] Johnson & Johnson. (n.d.). Invokana® (canagliflozin) Tablets. Retrieved from https://www.invokana.com/
[8] Bhatt, D. L., et al. (2020). Sotagliflozin in Patients with Diabetes and Recent Myocardial Infarction. New England Journal of Medicine, 382(13), 1207-1218. doi:10.1056/NEJMoa2001006
